Galecto Total Current Assets vs Capital Surpluse Analysis

GLTO Stock

USD 5.30 0.21 3.81%

Galecto financial indicator trend analysis is much more than just examining Galecto latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Galecto is a good investment. Please check the relationship between Galecto Total Current Assets and its Capital Surpluse accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galecto. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Galecto Stock, please use our How to Invest in Galecto guide.

Total Current Assets vs Capital Surpluse

Total Current Assets vs Capital Surpluse Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Galecto Total Current Assets account and Capital Surpluse. At this time, the significance of the direction appears to have no relationship.

The correlation between Galecto's Total Current Assets and Capital Surpluse is 0.0. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Capital Surpluse in the same time period over historical financial statements of Galecto, assuming nothing else is changed. The correlation between historical values of Galecto's Total Current Assets and Capital Surpluse is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Galecto are associated (or correlated) with its Capital Surpluse. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Surpluse has no effect on the direction of Total Current Assets i.e., Galecto's Total Current Assets and Capital Surpluse go up and down completely randomly.

Correlation Coefficient

0.0

Relationship Direction	Flat
Relationship Strength	Insignificant

View All Relationships

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Capital Surpluse

Most indicators from Galecto's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Galecto current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galecto. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Galecto Stock, please use our How to Invest in Galecto guide.At this time, Galecto's Enterprise Value Over EBITDA is very stable compared to the past year. As of the 2nd of December 2024, Enterprise Value Multiple is likely to grow to 0.06, while Selling General Administrative is likely to drop about 9.8 M.

Galecto fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Short Long Term Debt Total	Property Plant And Equipment Net	Current Deferred Revenue	Property Plant And Equipment Gross
Total Assets		-0.07	0.19	0.98	0.82	-0.89	-0.27	0.46	0.89	0.58	0.6	0.39	0.96	0.05	-0.3	0.46	0.74	0.65	0.26	0.86	0.98	0.98	0.91	0.78	-0.63	0.76
Other Current Liab	-0.07		0.48	-0.08	0.28	0.09	-0.47	0.11	-0.09	0.41	0.54	0.52	0.05	-0.6	-0.67	-0.31	0.1	0.43	0.46	0.27	-0.1	-0.13	0.27	0.45	-0.4	0.48
Total Current Liabilities	0.19	0.48		0.19	0.27	0.08	-0.64	0.89	-0.08	0.45	0.64	0.52	0.06	0.36	0.01	-0.31	0.22	0.52	1.0	0.27	0.2	0.16	0.36	0.52	-0.51	0.55
Total Stockholder Equity	0.98	-0.08	0.19		0.86	-0.88	-0.35	0.47	0.88	0.56	0.62	0.33	0.95	0.02	-0.35	0.38	0.78	0.68	0.27	0.9	1.0	1.0	0.87	0.74	-0.69	0.72
Net Tangible Assets	0.82	0.28	0.27	0.86		-0.72	-0.68	0.38	0.72	0.64	0.82	0.4	0.86	-0.27	-0.7	0.08	0.84	0.93	0.34	0.99	0.84	0.84	0.79	0.76	-0.93	0.76
Net Debt	-0.89	0.09	0.08	-0.88	-0.72		0.04	-0.23	-1.0	-0.22	-0.3	-0.03	-0.95	0.19	0.38	-0.29	-0.46	-0.44	0.02	-0.76	-0.89	-0.9	-0.73	-0.54	0.45	-0.51
Retained Earnings	-0.27	-0.47	-0.64	-0.35	-0.68	0.04		-0.53	-0.03	-0.55	-0.84	-0.41	-0.24	0.04	0.5	0.39	-0.62	-0.89	-0.66	-0.62	-0.33	-0.3	-0.33	-0.48	0.9	-0.51
Accounts Payable	0.46	0.11	0.89	0.47	0.38	-0.23	-0.53		0.23	0.33	0.55	0.32	0.3	0.56	0.16	-0.2	0.28	0.5	0.91	0.4	0.5	0.46	0.46	0.5	-0.51	0.51
Cash	0.89	-0.09	-0.08	0.88	0.72	-1.0	-0.03	0.23		0.23	0.3	0.04	0.95	-0.19	-0.38	0.29	0.46	0.44	-0.02	0.76	0.89	0.9	0.74	0.54	-0.45	0.52
Non Current Assets Total	0.58	0.41	0.45	0.56	0.64	-0.22	-0.55	0.33	0.23		0.89	0.94	0.51	-0.07	-0.42	0.5	0.85	0.71	0.49	0.67	0.51	0.49	0.79	0.9	-0.66	0.91
Non Currrent Assets Other	0.6	0.54	0.64	0.62	0.82	-0.3	-0.84	0.55	0.3	0.89		0.78	0.56	-0.11	-0.57	0.09	0.84	0.93	0.68	0.82	0.59	0.57	0.75	0.87	-0.91	0.89
Other Assets	0.39	0.52	0.52	0.33	0.4	-0.03	-0.41	0.32	0.04	0.94	0.78		0.31	-0.04	-0.29	0.48	0.63	0.52	0.55	0.44	0.29	0.26	0.7	0.84	-0.46	0.85
Cash And Short Term Investments	0.96	0.05	0.06	0.95	0.86	-0.95	-0.24	0.3	0.95	0.51	0.56	0.31		-0.21	-0.5	0.37	0.69	0.64	0.14	0.9	0.95	0.95	0.88	0.75	-0.64	0.73
Net Receivables	0.05	-0.6	0.36	0.02	-0.27	0.19	0.04	0.56	-0.19	-0.07	-0.11	-0.04	-0.21		0.85	0.09	-0.08	-0.15	0.36	-0.26	0.05	0.03	-0.09	-0.1	0.15	-0.11
Common Stock Shares Outstanding	-0.3	-0.67	0.01	-0.35	-0.7	0.38	0.5	0.16	-0.38	-0.42	-0.57	-0.29	-0.5	0.85		0.13	-0.5	-0.64	-0.02	-0.68	-0.32	-0.33	-0.42	-0.46	0.64	-0.47
Inventory	0.46	-0.31	-0.31	0.38	0.08	-0.29	0.39	-0.2	0.29	0.5	0.09	0.48	0.37	0.09	0.13		0.42	-0.09	-0.27	0.16	0.34	0.35	0.5	0.41	0.14	0.38
Other Current Assets	0.74	0.1	0.22	0.78	0.84	-0.46	-0.62	0.28	0.46	0.85	0.84	0.63	0.69	-0.08	-0.5	0.42		0.82	0.28	0.85	0.74	0.73	0.75	0.76	-0.81	0.76
Other Stockholder Equity	0.65	0.43	0.52	0.68	0.93	-0.44	-0.89	0.5	0.44	0.71	0.93	0.52	0.64	-0.15	-0.64	-0.09	0.82		0.57	0.89	0.66	0.65	0.69	0.75	-0.99	0.77
Total Liab	0.26	0.46	1.0	0.27	0.34	0.02	-0.66	0.91	-0.02	0.49	0.68	0.55	0.14	0.36	-0.02	-0.27	0.28	0.57		0.34	0.28	0.23	0.42	0.57	-0.56	0.6
Net Invested Capital	0.86	0.27	0.27	0.9	0.99	-0.76	-0.62	0.4	0.76	0.67	0.82	0.44	0.9	-0.26	-0.68	0.16	0.85	0.89	0.34		0.89	0.88	0.84	0.8	-0.89	0.8
Total Current Assets	0.98	-0.1	0.2	1.0	0.84	-0.89	-0.33	0.5	0.89	0.51	0.59	0.29	0.95	0.05	-0.32	0.34	0.74	0.66	0.28	0.89		1.0	0.85	0.72	-0.67	0.7
Net Working Capital	0.98	-0.13	0.16	1.0	0.84	-0.9	-0.3	0.46	0.9	0.49	0.57	0.26	0.95	0.03	-0.33	0.35	0.73	0.65	0.23	0.88	1.0		0.84	0.7	-0.66	0.68
Short Long Term Debt Total	0.91	0.27	0.36	0.87	0.79	-0.73	-0.33	0.46	0.74	0.79	0.75	0.7	0.88	-0.09	-0.42	0.5	0.75	0.69	0.42	0.84	0.85	0.84		0.96	-0.65	0.95
Property Plant And Equipment Net	0.78	0.45	0.52	0.74	0.76	-0.54	-0.48	0.5	0.54	0.9	0.87	0.84	0.75	-0.1	-0.46	0.41	0.76	0.75	0.57	0.8	0.72	0.7	0.96		-0.71	1.0
Current Deferred Revenue	-0.63	-0.4	-0.51	-0.69	-0.93	0.45	0.9	-0.51	-0.45	-0.66	-0.91	-0.46	-0.64	0.15	0.64	0.14	-0.81	-0.99	-0.56	-0.89	-0.67	-0.66	-0.65	-0.71		-0.72
Property Plant And Equipment Gross	0.76	0.48	0.55	0.72	0.76	-0.51	-0.51	0.51	0.52	0.91	0.89	0.85	0.73	-0.11	-0.47	0.38	0.76	0.77	0.6	0.8	0.7	0.68	0.95	1.0	-0.72

Click cells to compare fundamentals

Galecto Account Relationship Matchups

Galecto fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	56.6M	171.6M	122.2M	73.2M	38.2M	36.3M
Other Current Liab	67K	2.3M	2.6M	7.3M	3.9M	3.5M
Total Current Liabilities	7.9M	5.6M	4.5M	11.1M	5.8M	7.2M
Total Stockholder Equity	48.5M	165.5M	117.2M	61.8M	32.3M	60.8M
Net Tangible Assets	(71.1M)	165.5M	117.2M	61.8M	71.0M	52.7M
Net Debt	(11.0M)	(162.7M)	(61.7M)	(32.0M)	(21.2M)	(22.3M)
Retained Earnings	(69.5M)	(104.4M)	(156.1M)	(217.7M)	(256.1M)	(243.3M)
Accounts Payable	3.3M	2.9M	1.5M	3.4M	1.7M	2.6M
Cash	11.3M	163.6M	62.6M	32.8M	21.5M	20.4M
Non Current Assets Total	529K	2.3M	12.1M	9.3M	1.5M	1.4M
Non Currrent Assets Other	231K	1.2M	2.0M	2.3M	1.1M	1.3M
Other Assets	231K	0.0	2.0M	2.3M	1.0	0.95
Cash And Short Term Investments	11.3M	163.6M	100.2M	60.2M	33.2M	31.5M
Net Receivables	41.1M	2.2M	2.3M	1.4M	1.7M	1.6M
Liabilities And Stockholders Equity	56.6M	171.6M	122.2M	73.2M	38.2M	36.3M
Non Current Liabilities Total	211K	541K	448K	328K	66K	62.7K
Capital Lease Obligations	298K	915K	847K	804K	249K	236.6K
Inventory	3.3M	3.3M	7.3M	2.3M	1.0	0.95
Other Current Assets	314K	3.5M	7.6M	2.3M	1.9M	2.9M
Total Liab	8.1M	6.1M	5.0M	11.4M	5.9M	7.5M
Net Invested Capital	(71.1M)	165.5M	117.2M	61.8M	32.3M	49.8M
Total Current Assets	56.1M	169.3M	110.1M	63.9M	36.8M	62.8M
Accumulated Other Comprehensive Income	(2.5M)	674K	(320K)	(244K)	380K	399K
Net Working Capital	48.2M	163.7M	105.6M	52.8M	30.9M	57.6M

Pair Trading with Galecto

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Galecto position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Galecto will appreciate offsetting losses from the drop in the long position's value.

Moving together with Galecto Stock

0.84	ME	23Andme Holding Upward Rally	Pair Corr
0.73	VALN	Valneva SE ADR	Pair Corr

Moving against Galecto Stock

0.8	DRUG	Bright Minds Biosciences Trending	Pair Corr
0.7	SABSW	SAB Biotherapeutics	Pair Corr
0.62	VCYT	Veracyte	Pair Corr
0.55	VERA	Vera Therapeutics	Pair Corr
0.42	DMAC	DiaMedica Therapeutics Trending	Pair Corr

The ability to find closely correlated positions to Galecto could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Galecto when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Galecto - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Galecto to buy it.

The correlation of Galecto is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Galecto moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Galecto moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Galecto can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Galecto offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Galecto's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Galecto Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Galecto Stock:

How To Invest In Galecto

Details

Is Galecto Stock a good investment?

Details

What is Galecto's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galecto. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Galecto Stock, please use our How to Invest in Galecto guide.

You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galecto. If investors know Galecto will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galecto listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(19.11)

Return On Assets

(0.34)

Return On Equity

(0.73)

The market value of Galecto is measured differently than its book value, which is the value of Galecto that is recorded on the company's balance sheet. Investors also form their own opinion of Galecto's value that differs from its market value or its book value, called intrinsic value, which is Galecto's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galecto's market value can be influenced by many factors that don't directly affect Galecto's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Galecto's value and its price as these two are different measures arrived at by different means. Investors typically determine if Galecto is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galecto's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Galecto Total Current Assets vs Capital Surpluse Analysis

Total Current Assets vs Capital Surpluse

Total Current Assets vs Capital Surpluse Correlation Analysis

Correlation Coefficient

Total Current Assets

Capital Surpluse

Galecto fundamental ratios Correlations

Galecto Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Galecto fundamental ratios Accounts

Pair Trading with Galecto

Moving together with Galecto Stock

Moving against Galecto Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Total Current Liabilities
Total Current Assets	+ 1.0	Total Stockholder Equity
Net Working Capital	+ 1.0	Total Stockholder Equity
Net Working Capital	+ 1.0	Total Current Assets
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Net Invested Capital	+ 0.99	Net Tangible Assets

Cash	- 1.0	Net Debt
Current Deferred Revenue	- 0.99	Other Stockholder Equity
Cash And Short Term Investments	- 0.95	Net Debt
Current Deferred Revenue	- 0.93	Net Tangible Assets
Current Deferred Revenue	- 0.91	Non Currrent Assets Other
Net Working Capital	- 0.9	Net Debt